Max Healthcare's Q1FY27 revenue jumped 15% year-on-year to Rs 2,835 crore. A brokerage maintained a 'BUY' rating with a target price of Rs 1,120, citing aggressive expansion plans despite near-term margin pressures.
Max Healthcare: BUY Rating, Rs 1,120 Target; Q1FY27 Revenue Surges 15%
Max Healthcare reported consolidated net revenue of Rs 2,835 crore in Q1FY27, a 15% increase year-on-year. Reader Takeaway: Aggressive expansion drives revenue; monitor oncology recovery and margin pressure. ## What just happened Max Healthcare announced its Q1FY27 financial results, showing a 15% year-on-year rise in consolidated net revenue to Rs 2,835 crore. Gross revenue grew 16% YoY to Rs 2,982 crore. Operating EBITDA increased by 15.5% YoY to Rs 684 crore, though margins compressed by 338 bps QoQ to 24.1% due to new bed operationalization and acquisition integration costs. Reported Profit After Tax (PAT) was Rs 358 crore, a 3.8% YoY increase. ## Why this matters A brokerage firm has reiterated a 'BUY' rating on Max Healthcare with a target price of Rs 1,120 per share, indicating an 11% upside potential from the current price of Rs 1,009. The rating is based on a 24x EV/EBITDA multiple for FY28. The company's strategic expansion and focus on higher-value payers are seen as key growth drivers, despite short-term margin pressures. ## The backstory Max Healthcare has been actively expanding its network. Over the past year, it added 630 operational beds. The company recently acquired Kalinga Hospital and Yerawada Properties Private Limited, planning a new 450-bed hospital in Pune. It also received approval to enter the for-profit medical education business. ## What changes now The company's Board approved Rs 425 crore for a new 202-bed brownfield tower at its Vaishali hospital. The acquisition of Yerawada Properties is complete, paving the way for the Pune hospital. The move into medical education with a projected CapEx of Rs 300 crore per college is a significant diversification. ## Risks to watch Axis Securities highlights risks including potential economic slowdown, high doctor attrition, and unplanned capital expenditure that could strain the balance sheet. Near-term margins are expected to remain under pressure for 2-3 quarters due to newly added brownfield beds. ## Peer comparison While specific peer data isn't in the filing, Max Healthcare's expansion strategy and focus on higher-value services place it within the competitive Indian healthcare sector. The company aims to leverage revised CGHS tariffs and insurance escalations to offset costs. ## Context metrics (time-bound) * Q1FY27 Net Revenue: Rs 2,835 crore (+15% YoY) * Q1FY27 Operating EBITDA: Rs 684 crore (+15.5% YoY) * ARPOB: Rs 81,900 (+5% YoY) * Network Occupancy: 75% * Revised CGHS tariffs expected to provide Rs 140 crore annual revenue uplift. * Insurance contracts' 6% price revision expected from September–October 2026. ## What to track next Investors should closely monitor the normalization of oncology revenues, expected by Q3 FY27, and full recovery by Q4 FY27. The successful integration of Kalinga Hospital and the development of new brownfield and greenfield projects in Vaishali and Pune are also key areas to watch.
